CRISPR Therapeutics AG reported financial results for the quarter ended June 30, 2026. The company generated $76 million in CASGEVY revenue, reflecting 151% year-over-year growth. Net loss narrowed to $91.2 million from $208.5 million in the prior year period, driven by reduced R&D and G&A expenses alongside increased collaboration revenue. Cash reserves rose to $2,364.4 million following a $585.4 million convertible senior notes issuance in March 2026. The FDA approved CASGEVY for children aged two and older with sickle cell disease or transfusion-dependent beta thalassemia. Additionally, the company initiated Phase 1 clinical trials for CTX340 targeting refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency. CRISPR Therapeutics AG is a biopharmaceutical company focused on developing transformative gene-based medicines using CRISPR/Cas9 technology.